Granulocyte-colony stimulating factors for secondary prevention of leucopenia in patients receiving chemotherapy.
Article
in English
| IMSEAR
| ID: sea-45188
ABSTRACT
OBJECTIVE:
To evaluate the effectiveness of GCSF as a secondary preventive adjunct to chemotherapy in the gynaecologic cancer patients who previously had grade 3-4 neutropenia or leucopenia from chemotherapy. MATERIAL ANDMETHOD:
We retrospectively reviewed the medical records of 94 chemotherapeutic cycles with GCSF as secondary prophylaxis in 29 patients with gynaecologic malignancy between January 1996 and April 2005.RESULTS:
The median age of the patients was 51 years (21-75). Most of the patients had ovarian cancers (19 cases, 65.6%). From secondary GCSF, grade 4 neutropenia was developed in 12 of 94 cycles (12.8%), and grade 4 leucopenia was developed in 5 of 94 cycles (5.3%). There were no patients developing febrile neutropenia after GCSF support.CONCLUSION:
Secondary GCSF prophylaxis was effective in preventing grade 4 leucopenia, grade 4 neutropenia, and febrile neutropenia.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Ovarian Neoplasms
/
Aged
/
Female
/
Humans
/
Risk Factors
/
Carboplatin
/
Granulocyte-Macrophage Colony-Stimulating Factor
/
Cisplatin
/
Paclitaxel
/
Adult
Type of study:
Etiology study
/
Risk factors
Language:
English
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS